DRMA: AI 评分 43/100 — AI 分析 (4月 2026)

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing pharmaceutical product candidates for medical and aesthetic skin conditions. Their lead product candidate, DMT310, targets acne, psoriasis, and rosacea, while DMT410 addresses hyperhidrosis and aesthetic conditions.

Key Facts: Price: $1.22 AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Dermata Therapeutics is a clinical-stage biotech pioneering innovative treatments for skin conditions like acne, rosacea, and hyperhidrosis, with lead candidates DMT310 and DMT410 poised to disrupt the dermatology market and address unmet patient needs, offering a notable market position.

DRMA是做什么的？

Dermata Therapeutics, Inc., founded in 2014 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to identifying, developing, and commercializing innovative pharmaceutical product candidates for various medical and aesthetic skin conditions. The company's primary focus is on addressing unmet needs in dermatology through targeted therapies. Dermata's lead product candidate, DMT310, has completed a Phase IIb clinical trial for the treatment of moderate-to-severe acne and a Phase Ib proof-of-concept (POC) trial for mild-to-moderate psoriasis. Furthermore, DMT310 is currently in a Phase 2 clinical trial for the treatment of moderate-to-severe rosacea. The company is also developing DMT410, which has completed Phase Ib POC trials for the treatment of hyperhidrosis and certain aesthetic conditions. Dermata's pipeline reflects its commitment to providing effective and convenient solutions for common and underserved dermatological conditions. By focusing on clinical-stage development and strategic partnerships, Dermata aims to deliver significant value to patients and shareholders alike.

DRMA的投资论点是什么？

Dermata Therapeutics presents a notable market position due to its promising pipeline of clinical-stage dermatology assets. The lead candidate, DMT310, has shown positive results in Phase IIb trials for acne and is progressing in trials for rosacea, addressing a significant market. DMT410 targets hyperhidrosis and aesthetic conditions, further expanding the potential market reach. With a market capitalization of $0.00B and a focused approach, Dermata offers substantial upside potential if clinical trials continue to be successful and lead to eventual commercialization. Key value drivers include positive clinical data readouts, strategic partnerships, and potential FDA approval for its lead candidates. The company's low beta of 0.55 suggests lower volatility compared to the broader market, making it an attractive option for risk-conscious investors.

DRMA在哪个行业运营？

Dermata Therapeutics operates within the dynamic biotechnology industry, specifically targeting the dermatology market. This market is characterized by increasing demand for innovative treatments for skin conditions such as acne, rosacea, psoriasis, and hyperhidrosis. The competitive landscape includes companies like ARTL (Arteriocyte, Inc.), ATXI (Avenue Therapeutics, Inc.), CARM (Carisma Therapeutics, Inc.), ELAB (Establishment Labs Holdings Inc.), and GTBP (GT Biopharma, Inc.), each pursuing different approaches to address these conditions. Dermata's focus on clinical-stage development and its lead candidates position it to capture a share of this growing market, estimated to reach billions of dollars in the coming years.

Biotechnology

Healthcare

DRMA有哪些增长机遇？

DMT310 for Acne: DMT310 has completed Phase IIb clinical trials for moderate-to-severe acne, a market projected to reach $5.5 billion by 2027. Positive Phase III trial results and subsequent FDA approval could drive significant revenue growth for Dermata. The company's focus on improving patient outcomes and reducing side effects provides a competitive edge in this large and growing market. The timeline for potential commercialization is estimated within the next 2-3 years, pending successful trial completion and regulatory approval.
DMT310 for Rosacea: The rosacea market is another significant opportunity for DMT310, with a projected market size of $2.6 billion by 2028. Currently in Phase 2 clinical trials for rosacea, positive data could lead to a new treatment option for this chronic skin condition. Dermata's focus on addressing the underlying causes of rosacea, rather than just managing symptoms, could differentiate its product from existing treatments. Commercialization could potentially occur within 3-4 years, contingent on trial outcomes and regulatory pathways.
DMT410 for Hyperhidrosis: DMT410 targets hyperhidrosis, a condition characterized by excessive sweating, with a market expected to reach $1.6 billion by 2025. Having completed Phase Ib POC trials, further development and clinical trials could position DMT410 as a novel treatment option. The company's focus on non-invasive and long-lasting solutions provides a competitive advantage. The timeline for potential market entry is estimated within 4-5 years, subject to clinical progress and regulatory approvals.
Aesthetic Applications of DMT410: Beyond hyperhidrosis, DMT410 is being explored for various aesthetic applications, representing a substantial growth opportunity. The global aesthetic medicine market is projected to reach $125 billion by 2030. Dermata's focus on innovative formulations and delivery systems could enable it to capture a share of this market. Further research and development are needed to fully realize this potential, with a commercialization timeline of 5-7 years.
Strategic Partnerships and Licensing: Dermata can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its product candidates. Collaborating with larger pharmaceutical companies or specialized dermatology firms can provide access to funding, expertise, and distribution networks. These partnerships can also validate Dermata's technology and increase its visibility within the industry. The timing and impact of these opportunities are dependent on ongoing clinical trial results and business development efforts.

DMT310 has completed Phase IIb clinical trial for treatment of moderate-to-severe acne.
DMT310 has completed Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis.
DMT310 is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
DMT410 has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions.
The company was incorporated in 2014 and is headquartered in San Diego, California.

DRMA提供哪些产品和服务？

Develop pharmaceutical product candidates for medical skin conditions.
Develop pharmaceutical product candidates for aesthetic skin conditions.
Focus on clinical-stage development of dermatology assets.
Conduct clinical trials to evaluate the safety and efficacy of product candidates.
Seek regulatory approvals for commercialization of products.
Explore strategic partnerships and licensing agreements.

DRMA如何赚钱？

Develop and patent novel pharmaceutical formulations.
Conduct clinical trials to demonstrate efficacy and safety.
Seek regulatory approval from agencies like the FDA.
Commercialize approved products through direct sales or partnerships.

Patients suffering from acne.
Patients suffering from rosacea.
Patients suffering from hyperhidrosis.
Individuals seeking aesthetic treatments.

Proprietary drug formulations and delivery systems.
Patent protection for key product candidates.
Clinical data demonstrating efficacy and safety.
Expertise in dermatology drug development.

什么因素可能推动DRMA股价上涨？

Upcoming: Phase 2 clinical trial results for DMT310 in rosacea (2026).
Upcoming: Potential initiation of Phase 3 trials for DMT310 in acne (2026-2027).
Ongoing: Continued development of DMT410 for hyperhidrosis and aesthetic applications.
Ongoing: Potential strategic partnerships and licensing agreements.

DRMA的主要风险是什么？

Potential: Clinical trial failures for DMT310 or DMT410.
Potential: Regulatory delays or rejection of product candidates.
Ongoing: Competition from larger pharmaceutical companies with greater resources.
Ongoing: Need for additional capital to fund clinical development and operations.
Potential: Dilution of shareholder value through future equity offerings.

DRMA的核心优势是什么？

Promising clinical-stage pipeline.
Proprietary drug formulations.
Experienced management team.
Focus on unmet needs in dermatology.

DRMA的劣势是什么？

Limited financial resources.
Dependence on clinical trial outcomes.
Small number of employees.
No currently marketed products.

DRMA有哪些机遇？

Positive clinical trial results.
Strategic partnerships and licensing agreements.
Expansion into new dermatology indications.
FDA approval and commercialization of products.

DRMA面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Dilution of shareholder value through fundraising.

DRMA的竞争对手是谁？

Arteriocyte, Inc. — Focuses on regenerative medicine. — (ARTL)
Avenue Therapeutics, Inc. — Develops IV tramadol for post-operative pain. — (ATXI)
Carisma Therapeutics, Inc. — Develops CAR-M macrophage therapeutics. — (CARM)
Establishment Labs Holdings Inc. — Focuses on breast implants and aesthetic surgery. — (ELAB)
GT Biopharma, Inc. — Develops cancer immunotherapies. — (GTBP)

Key Metrics

Price: $1.22 (+0.83%)
MoonshotScore: 43/100

常见问题

What does Dermata Therapeutics, Inc. (DRMA) do?

Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. Their lead product candidate, DMT310, is being developed for acne, rosacea, and psoriasis, while DMT410 targets hyperhidrosis and aesthetic applications. The company aims to address unmet needs in dermatology by providing innovative and effective treatment options to patients.

Is DRMA stock a good buy?

Evaluating whether DRMA stock is a good buy requires careful consideration of its clinical-stage nature and potential. The company's lead product candidate, DMT310, has shown promise in Phase IIb trials for acne and is progressing in trials for rosacea. Positive clinical data and potential FDA approval could drive significant upside. However, the company's limited financial resources and dependence on clinical trial outcomes pose risks. Investors should weigh the potential rewards against the inherent risks associated with investing in a clinical-stage biotechnology company before making a decision.

What are the risks of investing in DRMA?

Investing in Dermata Therapeutics (DRMA) carries several risks inherent to clinical-stage biotechnology companies. These include the risk of clinical trial failures for DMT310 or DMT410, which could significantly impact the company's value. Regulatory hurdles and potential delays in obtaining FDA approval also pose risks. Furthermore, DRMA faces competition from larger pharmaceutical companies with greater resources. The company's need for additional capital to fund clinical development and operations could lead to dilution of shareholder value through future equity offerings.

What catalysts could move DRMA stock?

Several catalysts could potentially move DRMA stock in the near to medium term. Positive results from the ongoing Phase 2 clinical trial for DMT310 in rosacea could significantly boost investor confidence. The initiation of Phase 3 trials for DMT310 in acne would also be a positive catalyst. Furthermore, any strategic partnerships or licensing agreements could provide validation of Dermata's technology and attract additional investment. Ultimately, FDA approval and commercialization of any of its product candidates would be the most significant catalyst for DRMA stock.

What is DRMA stock price target?

As of March 3, 2026, there is no readily available analyst consensus price target for DRMA stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed financial model incorporating projected revenues, expenses, and discount rates, based on the potential success of DMT310 and DMT410. Investors should conduct their own due diligence and consider the inherent risks and uncertainties associated with clinical-stage biotechnology companies when evaluating DRMA's potential value.